Pharm Exec: Doubling Down On Innovation, Recovery (Young & Partners article – September 2021)

Devin Maraj2021-09-16T20:12:39+00:00September 16th, 2021|Featured, Our Publications|

While activity and outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable

Biotechnology Industry Merger and Acquisition Trends

Devin Maraj2021-08-30T16:21:46+00:00August 30th, 2021|Biotechnology Industry - Merger and Acquisition Trends|

Chemical Industry Merger and Acquisition Trends

Devin Maraj2021-08-30T15:59:12+00:00August 30th, 2021|Chemical Industry - Merger and Acquisition Trends, Issues & Trends|

Pharm Exec: Doubling Down On Innovation, Recovery (Young & Partners article – September 2021)

Devin Maraj2021-09-16T20:12:39+00:00September 16th, 2021|Featured, Our Publications|

While activity and outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable

Biotechnology Industry Merger and Acquisition Trends

Devin Maraj2021-08-30T16:21:46+00:00August 30th, 2021|Biotechnology Industry - Merger and Acquisition Trends|

Chemical Industry Merger and Acquisition Trends

Devin Maraj2021-08-30T15:59:12+00:00August 30th, 2021|Chemical Industry - Merger and Acquisition Trends, Issues & Trends|

Pharm Exec: Doubling Down On Innovation, Recovery (Young & Partners article – September 2021)

Devin Maraj2021-09-16T20:12:39+00:00September 16th, 2021|Featured, Our Publications|

While activity and outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable

Biotechnology Industry Merger and Acquisition Trends

Devin Maraj2021-08-30T16:21:46+00:00August 30th, 2021|Biotechnology Industry - Merger and Acquisition Trends|

Chemical Industry Merger and Acquisition Trends

Devin Maraj2021-08-30T15:59:12+00:00August 30th, 2021|Chemical Industry - Merger and Acquisition Trends, Issues & Trends|